We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 5 september 2018

The Lancet: [Comment] Risk factor policies, morbidity, and mortality in Russia

[Comment] Risk factor policies, morbidity, and mortality in Russia
Mortality rates in Russia decreased for non-communicable diseases and all other major causes of death between 1980 and 2016 according to the Global Burden of Disease (GBD) 2016 Study by the GBD 2016 Russian Collaborators,1 published in The Lancet. As the prevalence of the most important risk factor according to this study—high blood pressure—increased over the past decades,2 these achievements seem to be primarily due to substance control policies, specifically WHO's so-called best buys,3 which resulted in marked declines in tobacco4 and—more importantly for Russia—alcohol use.
Read more

[Articles] Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
Administration of brexanolone injection for post-partum depression resulted in significant and clinically meaningful reductions in HAM-D total score at 60 h compared with placebo, with rapid onset of action and durable treatment response during the study period. Our results suggest that brexanolone injection is a novel therapeutic drug for post-partum depression that has the potential to improve treatment options for women with this disorder.
Read more

[Articles] Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
In a broad all-comers population of patients requiring stent implantation for myocardial ischaemia, the FIREHAWK was non-inferior to the XIENCE as assessed with the primary endpoint of target lesion failure at 12 months and in-stent late lumen loss at 13 months. The FIREHAWK is a safe and effective alternative stent to treat patients with ischaemic coronary artery disease in clinical practice.
Read more

[Comment] How far will the FIREHAWK stent fly?
Symptomatic coronary artery disease has a high disease and health-care burden globally and percutaneous coronary intervention is one of the most common medical procedures worldwide, with around 4 million procedures done in 2016.1 Until 2022, the worldwide volume of procedures is forecast to expand by an average of 3–4% per year, with the greatest growth in Asia.2
Read more

[Editorial] Putting quality and people at the centre of health systems
The burden of mortality attributable to poor care is larger than that due to lack of access to care. Significant loss of life could be avoided if measures were put in place to guarantee quality of care. These striking conclusions are the result of the work by Margaret Kruk and colleagues, published in The Lancet, which informed the Commission published by The Lancet Global Health—High-quality health systems in the Sustainable Development Goals era: time for a revolution. Under development for the past 2 years with a team of 30 commissioners led by Kruk and Muhammed Pate, the Commission concludes that without quality health systems are ineffective and Sustainable Development Goal 3—to ensure healthy lives and promote wellbeing for all, at all ages—will not be achieved.
Read more